Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma	Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, angiosarcoma, connective tissue neoplasm, liposarcoma, neoplasm, osteosarcoma, sarcoma, vascular cancer	Active, not recruiting	Phase 2	2026-06-22		NCT04668300

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
M.D. Anderson Cancer Center	1145
National Cancer Institute (NCI)	3015

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
M D Anderson Cancer Center	Houston	United States	667

Clinical trials